Page last checked
Does Mounjaro cause fatigue?
Mounjaro’s common-reaction table does not list fatigue. Zepbound’s label does, but its figures are not a Mounjaro rate. Both contain tirzepatide, yet their labels describe different study groups.
What the product trials found
Zepbound
| Dose / group | Rate |
|---|---|
| Placebo958 people | 3% |
| 5 mg630 people | 5% |
| 10 mg948 people | 6% |
| 15 mg941 people | 7% |
Wegovy
| Dose / group | Rate |
|---|---|
| Placebo1,261 people | 5% |
| 2.4 mg2,116 people | 11% |
Groups fatigue and weakness
| Dose / group | Rate |
|---|---|
| Placebo303 people | 5% |
| 2.4 mg304 people | 9% |
| 7.2 mg1,311 people | 11% |
Information checked 2026-09-07
How these findings apply
Compound summary coverage
Compounds that list it
6 of 42
Only in a combined category
1
No reaction list in this guide
16
Best available source
FDA label
Which compound summaries list fatigue
The compound summaries show selected reaction entries. The product guide above keeps Mounjaro’s findings separate from those for Zepbound and Wegovy.
◆ Fatigue across 42 compoundsguide or source for every row
| Compound | How it appears | Frequency reported | Source type |
|---|---|---|---|
| TirzepatideZepbound, Mounjaro | Fatigue | Common (1–10%) | FDA labelRead source |
| SemaglutideWegovy, Ozempic, Rybelsus | Fatigue | Common (1–10%) | FDA labelRead source |
| LiraglutideVictoza, Saxenda | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | FDA label |
| Retatrutide | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | Human trial |
| Cagrilintide | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | Human trial |
| Survodutide | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | Human trial |
| BPC-157 | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| TesamorelinEgrifta SV, Egrifta WR | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | FDA label |
| PT-141Vyleesi | Fatigue | Reported in ≥2% and more often than placebo (24 weeks) | FDA labelRead source |
| CJC-1295 | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | limited human data |
| Ipamorelin | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | Human trial |
| TB-500 | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| GHK-Cu | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| Sermorelin | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | limited human data |
| MOTS-c | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| AOD-9604 | Fatigue | Reported in human safety work that reaches this page only through a review — no rate is published | limited human dataRead source |
| NAD+ | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | limited human data |
| Epitalon | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| Kisspeptin-10 | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| DSIP | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | limited human data |
| Hexarelin | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | limited human data |
| IGF-1 LR3 | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| PEG-MGF | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| LL-37 | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | limited human data |
| KPV | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| Thymosin alpha-1 | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | limited human data |
| SS-31Forzinity | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | FDA label |
| Semax | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | limited human data |
| Selank | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| Melanotan II | Drowsiness and tirednesscounted inside a grouped figure, not on its own | Graded moderate in one of the two subjects who reached 0.03 mg/kg — the finding that set the trial’s recommended dose one step lower | limited human dataRead source |
| Mazdutide | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | Human trial |
| Pinealon | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | limited human data |
| AHK-Cu | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| VK2735 | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | Human trial |
| Zenagamtide | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | Human trial |
| Pemvidutide | Not listed in this summaryThis short reaction list does not include the symptom. Check the full product label or study for more detail. | — | Human trial |
| Brenipatide | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| Eloralintide | Fatigue | Phase 2 Eloralintide groups: 0% to 46%, versus 11% with placebo | Human trialRead source |
| Enicepatide | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| Macupatide | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| MariTide | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
| Petrelintide | No reaction list in this guideThis guide has no reaction entries. That does not establish that no human safety evidence exists. | — | no human dose shown to work |
What people reported to the FDA
The first table summarizes labels and published trials. This table shows reports filed with the FDA after the medicines went on sale. Each percentage is the share of reports for that product that mention this symptom—not the share of patients who experienced it.
| Product | Share of its own reports | All reports |
|---|---|---|
| Saxendaliraglutide | 4.3% of Saxenda reports | 10,040 reports |
| Wegovysemaglutide | 4.2% of Wegovy reports | 21,044 reports |
| Ozempicsemaglutide | 4.2% of Ozempic reports | 66,161 reports |
| Rybelsussemaglutide | 4.0% of Rybelsus reports | 7,379 reports |
| Zepboundtirzepatide | 3.5% of Zepbound reports | 70,141 reports |
| Victozaliraglutide | 3.2% of Victoza reports | 44,086 reports |
| Trulicitydulaglutide | 2.8% of Trulicity reports | 88,332 reports |
| Mounjarotirzepatide | 2.7% of Mounjaro reports | 93,975 reports |
3Read deeper
Why a reaction table cannot explain your tiredness
Tiredness can have more than one explanation. A clinician can review when it started, other symptoms, food and fluid intake, and the rest of your medicines.
The Mounjaro label warns about low blood sugar, especially with insulin or a sulfonylurea. Its warning signs can include weakness and dizziness. Those symptoms should not simply be labeled ordinary fatigue.
Low blood sugar is a separate concern
What timing can tell you
The tables checked here do not give a set duration for fatigue. Reports that stomach and gut reactions become less common over time do not establish the same pattern for tiredness.
Note when the symptom began and whether it followed a dose change or another change in your health. That context can help a clinician assess it.
What the evidence shows—and what remains unknown
Keep a finding tied to the product and symptom that the source measured.
| The claim | What the evidence shows |
|---|---|
| Zepbound’s fatigue rate is also Mounjaro’s rate. | Not supported. The products contain the same drug but their labels report different trials. |
| Missing from the common-reaction table means it cannot happen. | Not supported. A table includes reactions that meet its reporting rules; it is not a complete account of every possible symptom. |
| The medicine explains my tiredness. | A trial table cannot establish the cause for one person. That needs a clinical assessment. |
| Fatigue will wear off after a set time. | These tables do not establish a timetable for fatigue. |
When tiredness needs medical attention
Weakness, dizziness or trouble concentrating can occur with low blood sugar or dehydration. The warnings below describe concerns that may need prompt medical attention.
Acute kidney injury from dehydration
PromptHypoglycemia when combined with insulin or a sulfonylurea
PromptCommon questions
Is fatigue listed on the Mounjaro label?
It is not listed in the common-reaction table checked here. That is a limited finding about that table, not proof that nobody taking Mounjaro becomes tired.
Zepbound lists fatigue in its own trials. Those figures should not be relabeled as Mounjaro results.
How long does Mounjaro fatigue last?
The tables checked here do not provide a set duration. The cause and course of tiredness can differ between people.
Does semaglutide cause fatigue as well?
Wegovy’s label lists fatigue. This is a product-specific finding and should not be transferred to all semaglutide products.
Rates from separate trials cannot show which drug will cause less tiredness for you.
Is fatigue worse when the dose goes up?
Mounjaro’s common-reaction table does not provide a fatigue row to answer that question. Zepbound reports fatigue by dose, but those are different trials.
A pattern for nausea or vomiting should not be used to predict fatigue.
Could the tiredness be low blood sugar rather than the compound?
Low blood sugar is a labeled concern, especially with insulin or a sulfonylurea. Its symptoms can include weakness, shakiness, sweating and dizziness.
Symptoms alone cannot establish the cause. Follow the care guidance from your clinician and seek help for severe symptoms.
Should I stop taking it if I am exhausted?
Contact your prescribing clinician to discuss the symptom and whether treatment needs to change. Describe when it began, how severe it is and any other symptoms.
Is fatigue the same as the tiredness people report after eating less?
A reaction table cannot separate those causes for one person. Food intake, other medicines and health changes are useful context for a clinical assessment.
The full profile for each compound
Want the full picture for one compound? Open its guide for uses, dosage information, side effects and serious warnings.
Tirzepatide reactions in full, including fatigue
What else semaglutide lists besides fatigue
Constipation read the same way as fatigue
Nausea across every page, as with fatigue
Find compound information beyond fatigue
Every AOD-9604 reaction, not only fatigue
Every Melanotan II reaction, not only fatigue
Reading fatigue for a length nobody published
What else eloralintide lists besides fatigue
Questions readers ask
How can I combat fatigue on Mounjaro?
What are four warning signs of fatigue?
How to get rid of fatigue on GLP-1?
- Zepbound (tirzepatide) — FDA-approved Prescribing Informationretrieved 2026-09-19FDA label
- Wegovy (semaglutide) — FDA-approved Prescribing Information (DailyMed)retrieved 2026-08-20FDA label
- Saxenda (liraglutide) injection — FDA-approved Prescribing Information (DailyMed)retrieved 2026-09-19FDA label
- VYLEESI (bremelanotide) injection — FDA-approved Prescribing Information (DailyMed SPL)retrieved 2026-09-19FDA label
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026;17 — Table 1, AOD9604 safety-signal row, sourced there to Stier 2013retrieved 2026-08-12limited human data
- Dorr RT, Lines R, Levine N, Brooks C, Xiang L. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-84retrieved 2026-08-13limited human data
- Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020;9(3):219-222retrieved 2026-08-13limited human data
- NCT06230523 — 48-week Phase 2 Eloralintide trialretrieved 2026-08-29Human trial
- MOUNJARO (tirzepatide) injection — DailyMed SPL, sections 5, 6.1, 8.4 and 14.6retrieved 2026-09-13FDA label
- ZEPBOUND (tirzepatide) injection — DailyMed SPL, sections 5 and 6.1retrieved 2026-09-13FDA label